Advanced Malignant Neoplasm Completed Phase 2 Trials for Oxybenzone (DB01428)

IndicationStatusPhase
DBCOND0033490 (Advanced Malignant Neoplasm)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01867294Spironolactone in Preventing Rash in Patients With Advanced Cancer Receiving Panitumumab and CetuximabSupportive Care